If frequent bathroom trips, a weak urine stream, or interrupted sleep have you searching for relief, prostate supplements can sound appealing. Their labels often promise better urinary flow or support for a healthy prostate. But what can they actually do?
Some supplements may offer modest relief from urinary symptoms, but they have not been shown reliably to shrink an enlarged prostate or prevent BPH complications. Evidence varies by ingredient and formulation. Saw palmetto, the best-known option, has largely failed to outperform placebo in high-quality trials. Other products have encouraging findings, but important gaps remain.
What is an enlarged prostate?
Benign prostatic hyperplasia (BPH) is noncancerous growth of prostate tissue that can enlarge the gland. Because the prostate surrounds the urethra, enlargement can interfere with urine flow. Symptoms may include difficulty starting urination, a weak stream, urgency, or waking at night to urinate.
However, urinary symptoms can have other causes, including bladder problems and infection. Prostate size alone does not predict how severe symptoms will be. An evaluation helps establish the cause before you choose a treatment.
Does saw palmetto work for an enlarged prostate?
Saw palmetto, also called Serenoa repens, is one of the most extensively studied herbal supplements for BPH. Despite its popularity, the strongest evidence does not support dependable symptom relief.
In the NIH-funded CAMUS randomized trial, increasing saw palmetto to three times the standard study dose did not improve urinary symptoms more than placebo. Taking more did not overcome the lack of benefit.
A 2023 Cochrane review likewise found that saw palmetto alone provides little or no improvement in urinary symptoms or quality of life compared with placebo.
Why do some studies sound more positive? Saw palmetto extracts differ in composition. European urology guidelines give a weak recommendation for hexane-extracted saw palmetto for men who particularly wish to avoid treatment-related sexual side effects, while stressing that benefits may be modest. This does not establish that every saw palmetto product works.
Can beta-sitosterol improve urinary flow?
Beta-sitosterol is a plant sterol found in some prostate supplements. Older randomized trials suggest that certain beta-sitosterol preparations may improve urinary symptoms and flow in men with mild to moderate BPH.
A 1999 Cochrane review of beta-sitosterol preparations included four trials involving 519 men, lasting four to 26 weeks. Certain preparations improved symptoms and flow, but did not significantly reduce prostate size. Long-term effectiveness, safety, and prevention of complications remain uncertain.
These findings need careful interpretation: Cochrane now identifies its older supplement summaries as outdated evidence of historical interest. They do not establish a current standard treatment or prove that a supplement can prevent urinary retention or eliminate the need for medical care.
What about pygeum and rye grass pollen?
These plant-based products are often grouped as phytotherapies, but their evidence should be considered separately.
Pygeum
Pygeum comes from the bark of the African plum tree, Prunus africana. A 2002 review of pygeum trials found possible improvements in urinary symptoms and flow. The trials were generally short and had methodological limitations; this is older evidence, not an up-to-date demonstration of effectiveness.
Rye grass pollen
A particular rye grass pollen preparation called Cernilton has also been studied for BPH. An older review of Cernilton trials reported modest improvement in some urinary symptoms, but not in urine flow. The small, short studies do not establish long-term effectiveness or safety, and their findings cannot be assumed to apply to other pollen extracts.
Do lycopene and selenium supplements help BPH?
Lycopene, a pigment found in tomatoes, has been investigated alone and in combination with other ingredients.
A six-month pilot trial involving 40 men reported improvements in symptom scores and no further prostate enlargement in the lycopene group. However, this small study does not establish reliable prostate shrinkage, lasting symptom relief, or prevention of BPH complications.
Combination products require another distinction. In the 2014 PROCOMB trial, 225 men received a specific saw palmetto–lycopene–selenium preparation, tamsulosin, or both. At one year, the group receiving both had greater improvements in symptom scores and peak urinary flow than either treatment alone.
Those results concern a particular formulation and selected study population. They do not prove that selenium alone helps BPH, that every prostate blend works, or that a supplement can replace tamsulosin. The broader Cochrane evidence on saw palmetto combinations remains uncertain.
What about pumpkin seed, stinging nettle, and other natural remedies?
Pumpkin seed, stinging nettle, and other extracts appear in many prostate health products. Their traditional use and proposed biological effects can sound persuasive, but clinical evidence remains limited or inconsistent.
When reviewing a claim, look beyond “clinically studied ingredients.” Ask whether the finished product was tested, what outcome improved, and how long participants were followed.
Are prostate supplements safe to take?
“Natural” does not guarantee that a product is appropriate for you. Supplements may cause side effects, interact with medicines, or duplicate ingredients in other products.
The FDA does not approve dietary supplements for safety and effectiveness before sale. A product’s availability therefore does not establish that it treats BPH.
Before starting one:
Bring the full ingredient list and serving size to your clinician or pharmacist.
Include every medicine, vitamin, and supplement you already take.
Ask whether the product has evidence relevant to your symptoms.
Agree on a follow-up plan and what would count as meaningful improvement.
Avoid replacing prescribed treatment without discussing the change.
Saw palmetto is generally well tolerated in studies, but reported side effects include digestive symptoms, dizziness, and headache. Tolerability should be weighed separately from effectiveness.
What natural approaches can help manage BPH symptoms?
Lifestyle changes may help manage urinary symptoms, particularly when symptoms are mild. Options include reducing caffeine and alcohol, adjusting fluid intake before bedtime, staying physically active, and avoiding holding urine for long periods. Maintain adequate hydration and discuss fluid changes with your clinician, especially if you have other health conditions.
A brief symptom diary can make the appointment more useful. Record bathroom trips, nighttime awakenings, drinks, and how symptoms affect daily activities. Bring specific goals, such as sleeping with fewer interruptions or feeling more comfortable during travel.
When should you consider medical treatment?
If symptoms remain bothersome, an evaluation can help you compare options beyond supplements.
BPH medicines work in different ways. Alpha-blockers relax muscle around the prostate and bladder neck to improve symptoms. For selected patients, 5-alpha-reductase inhibitors such as finasteride or dutasteride can shrink the gland over several months. Procedures may be considered when symptoms remain bothersome, or complications develop. Your evaluation and preferences guide the choice.
At North Star Prostate Center, a urology evaluation can help clarify your symptoms and treatment options. For eligible patients, the team also offers prostate artery embolization (PAE). Discuss expected benefits, risks, recovery, possible sexual side effects, and the chance of needing further treatment before choosing a procedure.
Seek urgent medical care if you cannot urinate, have fever and chills with painful urinary symptoms, or develop severe lower abdominal pain. Blood in the urine also needs prompt medical evaluation.
Get help choosing your next step
Bring your supplement bottles, medication list, and questions to the appointment. Schedule an evaluation with North Star Prostate Center to discuss a personalized plan for managing enlarged prostate symptoms.
This article provides general education and does not replace individualized medical advice.
Free Men’s Health Screening at North Star Prostate Center
Waking up several times at night to use the bathroom? Noticing a weaker urine stream or changes in sexual health?
These changes can happen gradually, making it difficult to know when to seek help. A free men’s health screening offers a simple way to better understand your symptoms and explore whether further evaluation may be helpful.
Our free, 10–15-minute screening is designed for men who want to take a proactive approach to their prostate, urinary, and sexual health.
Noticing Changes in Your Urinary or Sexual Health?
Changes in urinary habits or sexual function are common, particularly as men get older. However, that doesn’t mean you have to ignore them or figure out what’s happening on your own.
You may benefit from a men’s health screening if you’ve noticed:
Frequent urination: Needing to use the bathroom more often than usual.
Waking up at night: Getting out of bed repeatedly to urinate.
Weak urine stream: Having difficulty starting urination or noticing reduced flow.
Incomplete bladder emptying: Feeling like you still need to urinate after finishing.
Changes in sexual function: Noticing differences in erectile function or sexual performance.
Changes from your usual routine: Feeling that something about your urinary or sexual health isn’t quite the same.
These symptoms can have several possible causes, including age-related prostate enlargement, urinary conditions, or other health factors.
A free screening can help you better understand these changes and determine whether additional medical evaluation is appropriate.
What Is Included in Your Free Men’s Health Screening?
Your appointment takes less than 30 minutes and includes brief assessments designed to provide useful information about your urinary, prostate-related, sexual, and general vascular health.
Prostate and Urinary Symptom Assessment
Using the International Prostate Symptom Score (IPSS), you’ll answer a few questions about urinary frequency, nighttime urination, weak stream, and other symptoms.
This questionnaire helps measure how much your urinary symptoms are affecting your daily life.
Sexual Health Screening
A brief questionnaire called the Sexual Health Inventory for Men (SHIM) helps assess changes in erectile function.
Your responses can help identify whether additional discussion or evaluation may be beneficial.
Bladder Scan
A non-invasive bladder scan measures the amount of urine remaining in your bladder after urination, known as post-void residual (PVR).
This information may help identify bladder-emptying concerns that warrant further evaluation.
Circulation Screening
An ankle-brachial index (ABI) assessment compares blood pressure measurements in the arms and ankles to help identify possible circulation concerns.
Together, these screening components help guide a conversation about appropriate next steps.
What Happens After Your Screening?
Once your screening is complete, the experts at North Star Prostate Center will help you understand the recommended next step based on your results and symptoms.
Depending on your findings, this may include:
Monitoring and education: Guidance on symptoms to watch and when to seek additional care.
Specialist evaluation: A recommendation for further assessment if your symptoms or screening results suggest a possible health concern.
Discussion of treatment options: If a condition requiring treatment is identified through subsequent medical evaluation, your healthcare provider can explain which options may be appropriate.
The goal is to give you a clearer direction for your health without requiring a referral to get started.
Looking for a Free Prostate Exam? Here’s What to Know
If you searched for a “free prostate exam,” it’s helpful to understand what this appointment includes. Our free prostate and urinary health screening focuses on evaluating your symptoms through brief questionnaires and non-invasive assessments rather than a traditional prostate examination, PSA blood test, or rectal exam. It is intended to help determine whether further evaluation or testing may be appropriate.
Frequently Asked Questions
Who Can Schedule a Free Men’s Health Screening?
The screening is intended primarily for men ages 40 and older who have noticed changes in urinary habits, prostate-related symptoms, or sexual function, as well as those who want to better understand their health.
How Long Does the Screening Take?
The appointment typically takes approximately 10–15 minutes.
Do I Need a Referral?
No. You can schedule your free screening directly without a physician referral.
Is There a Cost for the Screening?
No. The screening appointment is free. If additional consultations, diagnostic testing, or treatment are recommended, those services are separate and may involve costs.
Will I Need a Rectal Exam?
No. The screening uses questionnaires and non-invasive assessments, including a bladder scan.
What If My Screening Identifies a Potential Concern?
The team can help you understand whether monitoring, further evaluation, or a specialist appointment may be appropriate. Screening results alone do not establish a diagnosis.
Take the First Step Toward Understanding Your Health
You don’t have to wait until urinary symptoms or changes in sexual health begin interfering with your daily routine.
A free men’s health screening offers a quick, convenient starting point to better understand what’s changing and what to do next.
Free. Approximately 15 minutes. No referral needed.
PAE and UroLift use different mechanisms to reduce urinary obstruction from BPH.
UroLift places permanent implants through the urethra to retract obstructing prostate tissue.
PAE is performed through an artery and reduces blood flow to selected prostate tissue, leading to gradual tissue shrinkage.
Current U.S. UroLift labeling includes lateral and median lobe hyperplasia in men aged 45 or older with prostates up to 100 cc.
PAE does not have the same device-based 100 cc upper-volume limit, but vascular anatomy and other clinical factors can affect candidacy.
Both treatments are commonly considered when preservation of sexual function is important, but neither procedure can guarantee unchanged erectile or ejaculatory function.
There is no direct randomized head-to-head trial proving that PAE or UroLift is superior for all patients.
Evaluation of urinary symptoms, prostate anatomy, bladder function, and treatment goals is essential before choosing either procedure.
Choosing between PAE, UroLift, or another BPH treatment starts with confirming what is causing the urinary symptoms. North Star combines urologic evaluation with PAE expertise so patients can better understand which treatment options fit their prostate anatomy, urinary function, medical history, and goals.
Prostate artery embolization (PAE) and UroLift, also called prostatic urethral lift (PUL), can both be used to treat bothersome lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). They are not interchangeable procedures, however. UroLift mechanically opens the prostatic urethra with permanent implants, while PAE reduces blood flow to selected prostate tissue so the gland can shrink over time. Neither treatment is automatically better for every patient. The more important question is which treatment, if either, fits the cause of the urinary symptoms, prostate size and anatomy, bladder function, symptom severity, previous treatment, medical history, and the patient’s priorities. Current evidence supports shared decision-making rather than choosing a procedure from prostate size or symptom score alone.
AtNorth Star Prostate Center, patients can approach that decision through multidisciplinary prostate care rather than beginning with the assumption that a specific procedure is the answer. North Star offers urology care alongside prostate artery embolization, bringing urologic evaluation and minimally invasive PAE expertise into the same setting. For someone comparing PAE vs. UroLift, that broader evaluation can help clarify whether PAE, a urologic treatment, or another management approach should be considered.
A systematic review and network meta-analysis found broadly similar outcomes for PAE and PUL, but the comparison was indirect and the authors rated the available evidence as relatively limited.
PAE vs UroLift
Feature
PAE
UroLift
How it works
Reduces arterial blood flow to selected prostate tissue so it shrinks over time
Retracts prostate tissue away from the urethra using small permanent implants
Treatment route
Catheter placed through an artery, commonly from the wrist or groin
Device passed through the urethra
Prostate tissue cut or resected
No
No
Thermal energy used
No
No
Permanent mechanical implant
No
Yes
Typical setting
Usually outpatient
Usually outpatient
General anesthesia
Often not required; sedation practices vary
Often not required; anesthesia approach varies
Symptom response
Usually develops over weeks as prostate tissue responds and shrinks
Can begin relatively quickly after the procedure; individual response varies
Catheter after treatment
May or may not be needed depending on baseline retention and recovery
Most patients do not typically require one, but temporary catheterization may be needed
Sexual function
Generally designed to avoid direct urethral or surgical injury; sexual side effects can still occur
Pivotal study reported no new sustained erectile or ejaculatory dysfunction
Prostate size
No device-based upper-volume indication; selection remains individualized
U.S. labeling: prostate volume up to 100 cc
Specialist
Interventional radiologist
Urologist
How Does UroLift Work?
UroLift treats obstruction by changing the position of prostate tissue rather than removing it. A urologist passes a delivery device through the urethra and places small implants that pull selected prostate tissue away from the urethral channel. The implants remain in place to keep the channel more open. According to current U.S. UroLift patient safety information, the system is indicated for urinary outflow obstruction from BPH, including lateral and median lobe hyperplasia, in men age 45 and older. It should not be used when prostate volume is greater than 100 cc and has other contraindications, including active urinary tract infection, current gross hematuria, urinary incontinence from an incompetent sphincter, and urethral conditions that prevent device insertion. Because the procedure does not cut, heat, or remove prostate tissue, UroLift is often discussed with patients who want a minimally invasive option and who place a high value on preserving ejaculation. Candidacy still depends on the individual anatomy and the clinician’s assessment.
How Does PAE Work?
PAE approaches the prostate through its arterial blood supply. An interventional radiologist advances a small catheter through an artery, maps the vessels supplying the prostate, and delivers embolic particles into selected prostatic arteries. The resulting reduction in blood flow causes ischemic change in targeted prostate tissue, followed by gradual reduction in prostate volume. PAE is technically demanding because pelvic arterial anatomy varies from patient to patient and branches supplying the prostate can communicate with nearby organs. Careful angiographic mapping is used to reduce the risk of non-target embolization. The Society of Interventional Radiology published updated PAE practice guidance in June 2026. At North Star, PAE is described as an outpatient treatment performed through a small arterial access site, generally without general anesthesia. Exact sedation, access route, medications, and post-procedure instructions are individualized.
Is PAE More Effective Than UroLift?
Current evidence does not justify saying that PAE is universally more effective than UroLift. Importantly, there is no randomized trial directly assigning patients to PAE versus UroLift. The best-known comparison is an indirect network meta-analysis of randomized trials that used TURP or sham treatment as common comparators. It found similar overall clinical efficacy and safety profiles for PAE and PUL, while also emphasizing that the evidence was limited and should be interpreted cautiously. See the BJU International review on PubMed. For an individual patient, a procedure may look more or less favorable depending on the treatment goal. Objective urinary flow, symptom relief, catheter dependence, desire to avoid permanent implants, prostate size, vascular anatomy, and preservation of sexual function can all carry different weight.
Does Prostate Size Matter for PAE or UroLift?
Yes, but prostate size is only one part of treatment selection. Current U.S. UroLift labeling states that the system should not be used when prostate volume is greater than 100 cc. The label includes treatment of lateral and median lobe hyperplasia. That is important because older articles and older guideline summaries may still describe narrower selection criteria. PAE is not governed by a fixed device-volume indication in the same way. It has been studied in populations with substantially larger prostates. For example, a 2025 single-center cohort of 1,075 PAE patients had a median prostate volume of 107 g. That study showed sustained symptom improvement in follow-up, but it was observational and should not be interpreted as proof that every large prostate is an appropriate PAE candidate. Review the study on PubMed. Prostate shape, intravesical protrusion, bladder function, arterial anatomy, prior prostate procedures, and the reason for the urinary symptoms can be as important as prostate volume.
Which Treatment Is Better for Preserving Sexual Function?
Both treatments are often considered when sexual side effects are a major concern, but the most accurate wording is that they have favorable sexual-function profiles in published studies, not that either procedure guarantees preservation. For UroLift, the current manufacturer safety page states that the pivotal study reported no new sustained erectile or ejaculatory dysfunction. Long-term follow-up of the L.I.F.T. study also reported preservation of sexual function through five years. Read the five-year UroLift study on PubMed. For PAE, randomized and systematic-review evidence generally shows little change in erectile function compared with baseline or TURP, and some evidence suggests fewer ejaculatory disorders than TURP. However, the certainty of evidence for several sexual-function outcomes is low, and ejaculatory changes can occur. See the Cochrane review on PubMed. Baseline erectile function, medications, age, diabetes, vascular disease, and other conditions can affect sexual outcomes regardless of which BPH procedure is selected.
How Does Recovery Compare?
Recovery After UroLift
UroLift is commonly performed as an outpatient procedure. According to current Teleflex patient information, most patients do not typically require a catheter. When a catheter is needed, the average duration reported by the manufacturer is about one day. Return to normal activity is often within a few days, although recovery varies. Temporary side effects can include painful or uncomfortable urination, urgency, urge incontinence, pelvic pain, and blood in the urine. Bleeding and infection are less common but can be serious. Review current UroLift safety information.
Recovery After PAE
PAE is also commonly performed on an outpatient basis. Patients may experience post-embolization symptoms such as burning with urination, pelvic or local pain, urinary frequency, fatigue, or other temporary irritative urinary symptoms. A systematic review found dysuria or urethral burning and local pain among the most commonly reported components of post-embolization syndrome. Read the systematic review on PubMed. Temporary catheterization is not required for every PAE patient, but acute urinary retention is a recognized adverse event and catheter needs depend on baseline retention, bladder function, prostate swelling, and the clinical course. Patients who already use a catheter require individualized planning.
What Are the Risks of PAE and UroLift?
Every BPH procedure has potential complications. A balanced comparison should include these risks rather than focusing only on recovery time.
Potential PAE Risks
Post-embolization symptoms such as pelvic pain, dysuria, urinary frequency, or fatigue.
Urinary tract infection or acute urinary retention.
Blood in the urine or semen.
Bleeding, bruising, or vascular complications at the arterial access site.
Need for repeat BPH treatment if symptoms recur or remain bothersome.
Potential UroLift Risks
Dysuria or discomfort with urination.
Urinary urgency or urge incontinence.
Pelvic pain.
Blood in the urine.
Temporary urinary retention or catheter use in some patients.
Bleeding or infection, which can rarely be serious.
Need for additional BPH treatment if symptoms persist or recur.
How Durable Are PAE and UroLift?
Both procedures can provide durable symptom improvement, but retreatment remains possible and study designs differ. The five-year L.I.F.T. study of UroLift reported a 13.6% surgical retreatment rate. That figure applies to the population and protocol studied and should not be presented as a guaranteed individual outcome. A 2025 observational study of 1,075 PAE patients reported that 16% of reintervention-eligible patients underwent a second prostatic intervention by up to 60 months. The study also reported sustained symptom improvement among patients with longer follow-up. Because this was not a randomized comparison with UroLift and the populations differed, the percentages should not be used to claim that one treatment is more durable than the other.
Who May Be Considered for UroLift?
UroLift may be discussed when urinary symptoms are attributed to BPH and prostate anatomy fits the device indication and treatment plan. Considerations may include:
Bothersome urinary symptoms linked to BPH.
A prostate volume within current U.S. device labeling.
Anatomy that the treating urologist believes can be effectively treated with PUL.
A preference to avoid tissue resection or thermal ablation.
A strong preference to preserve erectile and ejaculatory function.
Acceptance of permanent implants in the prostate.
Current labeling also lists contraindications that must be reviewed before treatment. A urologist determines whether the procedure is appropriate.
Who May Be Considered for PAE?
PAE may be discussed when a patient has bothersome LUTS attributed to BPH and wants to consider an arterial, non-resection treatment. Potential reasons to evaluate PAE include:
Persistent moderate to severe urinary symptoms despite conservative care or medication.
Medication side effects or a desire to discuss a procedural alternative.
A preference to avoid transurethral tissue treatment.
A large prostate or anatomy for which additional treatment options should be considered.
A desire to avoid a permanent mechanical prostate implant.
Concern about sexual side effects from other BPH treatments.
Medical factors that make treatment planning more complex and warrant multidisciplinary review.
PAE is not appropriate for every patient. Arterial anatomy, kidney function, contrast considerations, infection, prostate cancer evaluation when indicated, bladder function, and the true cause of urinary symptoms may affect candidacy.
What Testing Is Needed Before Choosing a BPH Procedure?
Lower urinary tract symptoms are not specific to BPH. Weak stream, urgency, frequency, incomplete emptying, and nocturia can also result from bladder dysfunction, urethral disease, infection, neurologic conditions, medication effects, or other causes. Depending on the patient, evaluation may include:
Medical and urinary symptom history.
International Prostate Symptom Score (IPSS).
Medication and prior-procedure review.
Urinalysis and other laboratory testing when indicated.
PSA testing and prostate cancer evaluation when appropriate.
Prostate volume and anatomy assessment.
Urinary flow measurement.
Post-void residual measurement.
Bladder function assessment or urodynamic testing in selected cases.
Imaging needed for treatment planning.
At North Star, this evaluation is an important part of treatment planning rather than simply a step toward PAE. The center offers in-house urology care alongside its PAE program, allowing urinary symptoms, prostate anatomy, bladder function, and other possible causes of lower urinary tract symptoms to be assessed before a procedural option is selected. This multidisciplinary approach can be especially useful for patients who are still deciding among PAE, UroLift, medication, or other BPH treatment approaches.
PAE Evaluation in Golden Valley and Minneapolis, Minnesota
North Star Prostate Center is located at 8401 Golden Valley Road, Suite 340, Golden Valley, Minnesota, and serves patients from Minneapolis, St. Paul, and surrounding Twin Cities communities. North Star Prostate Center focuses on helping men understand the cause of their urinary symptoms and the treatment options that may be appropriate for them. Its multidisciplinary urology and PAE capabilities allow patients comparing PAE vs. UroLift to review prostate size and anatomy, bladder function, previous treatment, medical history, recovery preferences, and personal priorities before deciding on the next step. The goal of the consultation is to determine treatment fit rather than assume that a particular procedure is right for every patient. Review North Star’s BPH information or contact the center to request an evaluation.
Medical disclaimer: This article is for general educational purposes and is not a substitute for individual medical advice. BPH treatment depends on the cause and severity of urinary symptoms, prostate size and anatomy, bladder function, medical history, medications, prior procedures, and personal goals. A qualified clinician should determine which options are appropriate for an individual patient.
Rezum uses water vapor generated by radiofrequency energy and treats the prostate through the urethra.
PAE reduces blood supply to selected prostate tissue through an arterial catheter.
Rezum has a current U.S. indication for men aged 50 or older with prostates from 30 to 80 cc, including central-zone and median-lobe hyperplasia.
PAE does not have the same device-based 30 to 80 cc indication and has been studied in men with larger prostates, but candidacy remains individualized.
Temporary catheter use for several days is common after Rezum because urinary symptoms can continue or worsen during the early healing phase.
PAE can also cause urinary irritation and acute urinary retention, so some patients may require temporary catheterization.
Published studies show favorable sexual-function profiles for both procedures, but sexual side effects can occur and cannot be ruled out.
Indirect comparisons suggest both procedures can improve BPH symptoms, but the certainty of comparative evidence is limited.
Selecting a BPH treatment should begin with determining the cause of the urinary symptoms and evaluating prostate anatomy and bladder function. North Star combines urologic evaluation with PAE expertise to help patients understand which treatment pathways may be appropriate.
Prostate artery embolization (PAE) and Rezum water vapor therapy are minimally invasive procedures used for lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). Both can reduce obstruction without surgically removing the prostate, but they treat prostate tissue in very different ways.
Rezum is performed through the urethra and delivers controlled water vapor into selected prostate tissue. PAE is performed through an artery and reduces blood flow to selected parts of the prostate. In both procedures, symptom improvement develops as the treated tissue changes over time rather than from immediate surgical removal of a large amount of tissue.
The question for patients is not simply whether PAE or Rezum is better. Treatment selection depends on confirming the cause of the urinary symptoms and considering prostate volume and anatomy, bladder function, urinary retention, medical history, previous treatment, and personal priorities. There is no direct randomized trial proving that PAE or Rezum is superior for every patient.
AtNorth Star Prostate Center, patients can approach that decision through multidisciplinary prostate care rather than beginning with the assumption that a specific procedure is the answer.
North Star provides urology care alongside its PAE program, helping patients understand their urinary symptoms and how PAE, urologic procedures such as Rezum, or other BPH management options may fit into their care.
PAE vs. Rezum
Feature
PAE
Rezum
How it works
Reduces arterial blood flow to selected prostate tissue, followed by gradual shrinkage
Uses controlled water vapor to create targeted thermal injury; treated tissue is gradually resorbed
Treatment route
Through an artery, commonly the wrist or groin
Through the urethra
Prostate tissue resected during procedure
No
No
Thermal energy
No
Yes
Permanent mechanical implant
No
No
U.S. labeled prostate volume
No device-based 30-80 cc indication; clinical selection is individualized
30-80 cc
Median lobe
Can be evaluated as part of individualized PAE planning
Current U.S. indication includes median lobe hyperplasia
General anesthesia
Often not required; sedation varies
Typically does not require general anesthesia; anesthesia varies
Catheter
May or may not be needed
Commonly needed for several days during early healing
Expected response
Usually evolves over weeks to months
May begin within weeks; maximum benefit can take about 3 months
Sexual function
Generally favorable profile, but sexual side effects remain possible
Five-year pivotal trial reported no procedure-related sexual dysfunction or sustained de novo erectile dysfunction
Specialist
Interventional radiologist
Urologist
What Is Rezum & How Does It Work?
Rezum is a transurethral water vapor therapy. A urologist passes the treatment device through the urethra and delivers short, controlled injections of sterile water vapor into selected obstructing prostate tissue. The vapor releases thermal energy within the tissue. Over time, the body’s healing response absorbs the treated tissue, decreasing the amount of tissue pressing on the urethra. Current U.S. Boston Scientific prescribing and safety information states that Rezum is intended for men aged 50 and older with prostate volume from 30 to 80 cubic centimeters. The indication includes hyperplasia of the central zone and/or a median lobe.
The procedure does not leave a permanent mechanical implant. It does create a controlled inflammatory and healing response, which is why urinary irritation and temporary catheter use can be part of the early recovery.
How Does PAE Work?
PAE is an image-guided endovascular procedure. An interventional radiologist advances a catheter through an artery and uses angiography to identify the vessels supplying the prostate. Embolic particles are then delivered into selected prostatic arteries to reduce blood flow. The treated tissue undergoes ischemic change and the prostate can decrease in volume over time. Because the prostate has variable arterial connections with the bladder, rectum, penis, and other pelvic structures, careful vessel mapping is central to the procedure. Non-target embolization is an uncommon but important potential complication. The Society of Interventional Radiology issued updated PAE practice guidance in June 2026.
North Star describes its PAE program as outpatient care generally performed without general anesthesia. The exact treatment plan depends on the patient.
Is PAE More Effective Than Rezum?
There is not enough direct evidence to say that PAE is universally more effective than Rezum, or vice versa. No major randomized trial has directly assigned patients to PAE versus Rezum and followed them head-to-head.
A systematic review and network meta-analysis comparing several minimally invasive BPH treatments found no consistently significant differences in symptom-score outcomes among PAE, Rezum, and other minimally invasive therapies at the time points available. However, comparisons were indirect, follow-up differed by treatment, and the evidence base was limited. Review the Journal of Vascular and Interventional Radiology analysis on PubMed.
Another network meta-analysis concluded that PAE, prostatic urethral lift, and water vapor thermal therapy can provide favorable risk-benefit profiles, while emphasizing that longer-term randomized comparisons are still needed. See the European Urology Focus analysis on PubMed.
For clinical decision-making, the important question is which procedure best fits the individual patient’s anatomy, urinary function, recovery preferences, and tolerance for procedure-specific risks.
Which Treatment Works Faster?
Both procedures generally require time for tissue response, but the early recovery patterns differ. After Rezum, temporary prostate swelling can cause ongoing or temporarily worse urinary symptoms. Boston Scientific patient information states that some patients notice symptom relief in as soon as two weeks and that maximum benefit may occur within approximately three months. Review Rezum recovery information.
After PAE, urinary symptoms usually improve gradually as the treated prostate responds to reduced blood flow and decreases in volume. Some men improve within the first several weeks, while additional change can occur over the following months. The timeline varies substantially, especially in men with severe obstruction, urinary retention, or impaired bladder contractility. Neither procedure should be presented as a guaranteed source of immediate relief. A patient who cannot urinate or has high-risk retention may need catheter drainage or other management while the underlying BPH treatment takes effect.
Will I Need a Catheter After PAE or Rezum?
Catheter Use After Rezum
Temporary catheterization is common after Rezum. Current Boston Scientific patient guidance states that men in the clinical study typically needed a catheter for about three days. The reason is that treated tissue can swell during the early healing phase, which can temporarily worsen obstruction. Some patients need a catheter for a shorter or longer period depending on prostate anatomy, baseline retention, post-void residual, and clinical recovery.
Catheter Use After PAE
PAE does not require a catheter for every patient, but urinary retention is a recognized possible adverse event. A patient who already depends on a catheter before treatment may need continued drainage during the early post-procedure period.
In a 2025 observational cohort, 119 of 126 catheter-dependent patients, or 94%, were catheter-free at three months after PAE. This was a single-center retrospective study, so the result should be presented as study data rather than a guaranteed success rate for every catheter-dependent patient. Review the 1,075-patient PAE cohort.
How Does Recovery Compare?
Rezum Recovery
Current patient guidance from Boston Scientific describes return to regular activities within a few days for many patients, but individual restrictions vary. The early healing period can include:
Painful or frequent urination.
Urgency.Blood in the urine or semen.
Pelvic or penile discomfort.
Temporary urinary retention or incomplete emptying.
Temporary catheter use.
Urinary tract infection in some patients.
Less common risks listed in current safety information include changes in ejaculatory volume, inability to ejaculate, worsening erectile dysfunction, urethral stricture, bladder-neck narrowing, and severe infection.
PAE Recovery
PAE is commonly performed without an overnight hospital stay, but recovery is not symptom-free for everyone. Post-embolization symptoms can include urinary burning, pelvic or local pain, urinary frequency, fatigue, and other temporary inflammatory symptoms.
A systematic review of 32 studies involving 2,116 patients found post-embolization syndrome was commonly reported after PAE, although definitions varied considerably across studies. Dysuria or urethral burning and local pain were among the most frequently reported components. Review the systematic review on PubMed.
Other recognized PAE risks include urinary tract infection, acute urinary retention, hematuria, hematospermia, access-site complications, and rare non-target embolization.
How Do PAE and Rezum Affect Sexual Function?
Both procedures have published data suggesting relatively favorable sexual-function outcomes, but neither should be described as having zero sexual risk.
In the pivotal randomized Rezum study, five-year follow-up reported a 4.4% surgical retreatment rate and no procedure-related sexual dysfunction or sustained de novo erectile dysfunction in the treated study population. A separate five-year sexual-function analysis also found preservation of erectile and ejaculatory function among assessed participants. Read the five-year Rezum trial and sexual-function analysis.
Current Rezum safety information nevertheless lists possible decreases in ejaculatory volume, anejaculation, worsening erectile dysfunction, and discomfort with ejaculation among potential adverse events. That is why the most accurate message is that sexual function is often preserved, not that sexual side effects cannot happen.
For PAE, systematic-review evidence suggests erectile function is often similar to baseline or to TURP, and ejaculatory disorders may be less common than after TURP. The certainty of several sexual-function comparisons remains low. Review the Cochrane evidence on PAE.
Does Prostate Size Matter?
Yes. This is one of the clearest differences in how the two procedures are described for U.S. patient selection.
The current U.S. Rezum indication is for prostate volume from 30 to 80 cc in men age 50 or older. It also includes central-zone and median-lobe hyperplasia. Patients outside that volume range should not be described as fitting the labeled device indication, even though studies may explore broader real-world use. See current Rezum product information.
PAE has been studied in men with larger prostates and does not use a device indication limited to 30 to 80 cc. The 2025 PAE cohort of 1,075 patients had a median prostate volume of 107 g, demonstrating that PAE is used in populations with larger glands. That does not mean prostate size alone makes someone a good PAE candidate. Review the PAE cohort on PubMed.
For both procedures, prostate anatomy, degree of obstruction, bladder function, urinary retention, and the patient’s broader medical situation must be considered alongside volume.
How Durable Are PAE and Rezum?
Both treatments have evidence of multi-year symptom improvement, but the studies are different enough that their retreatment percentages should not be treated as a direct contest.
The randomized Rezum study followed treated patients for five years and reported sustained symptom and flow improvements, with a 4.4% surgical retreatment rate in that study population. See the five-year trial on PubMed.
The 2025 PAE cohort reported sustained symptom improvement among patients with long-term follow-up and found that 16% of reintervention-eligible patients had a second prostatic intervention by up to 60 months. Because it was a retrospective single-center cohort, its percentage is not directly comparable with the randomized Rezum trial. See the PAE cohort on PubMed.
Durability should be discussed together with baseline prostate size, severity of obstruction, age, bladder function, medication use, and the possibility that BPH can continue to progress over time.
Who May Be Considered for Rezum?
A urologist may discuss Rezum when a patient has bothersome LUTS attributed to BPH and meets the clinical and device-selection requirements. Factors that can support discussion include:
Age 50 or older.
Prostate volume within the current 30 to 80 cc U.S. indication.
Lateral, central-zone, or median-lobe BPH that is appropriate for water vapor treatment.
A preference for a minimally invasive transurethral treatment rather than tissue resection.
A desire to avoid a permanent prostate implant.
A strong interest in preserving sexual function.
Acceptance of a healing period that commonly includes several days of catheter use and temporary urinary irritation.
Rezum is contraindicated in some circumstances, including active urinary tract infection and certain implanted urologic devices, so individual screening is required.
Who May Be Considered for PAE?
PAE may be discussed when a patient has urinary symptoms attributed to BPH and wants to consider a treatment delivered through the arterial system rather than through the urethra. Potential reasons for evaluation include:
Persistent moderate to severe BPH symptoms.
Insufficient relief from medication or medication side effects.
A preference to avoid transurethral thermal treatment or surgical tissue removal.
A prostate larger than the labeled Rezum range, when PAE and other options are being considered.
A desire to avoid a permanent mechanical implant.
Concern about sexual side effects from other BPH procedures.
Urinary retention or other complex symptoms that warrant multidisciplinary evaluation.
PAE still requires careful screening. Severe atherosclerotic disease, unfavorable pelvic arterial anatomy, renal function and contrast considerations, active infection, bladder dysfunction, and concern for another cause of urinary symptoms may change the treatment plan.
What Testing Is Needed Before Choosing PAE or Rezum?
BPH is only one possible cause of male lower urinary tract symptoms. An evaluation should establish whether the prostate is the main source of obstruction and whether the bladder can empty effectively.
Depending on the clinical situation, evaluation may include:
Urinary symptom history and International Prostate Symptom Score (IPSS).
Medication and prior BPH treatment history.
Urinalysis and infection assessment.
PSA testing and prostate cancer evaluation when indicated.
Prostate volume and anatomy assessment.
Urinary flow testing.
Post-void residual measurement.
Bladder-function evaluation or urodynamics in selected patients.
Imaging needed for PAE vascular planning or other procedural planning.
At North Star, the diagnostic evaluation helps guide the treatment discussion rather than simply determine eligibility for PAE. The center provides urology care for urinary flow and prostate concerns alongside its PAE program. Evaluating the cause of symptoms, prostate anatomy, urinary flow, bladder function, and previous treatment can help patients better understand whether PAE or another BPH treatment approach deserves consideration.
PAE for BPH in Golden Valley and Minneapolis, Minnesota
North Star Prostate Center is located at 8401 Golden Valley Road, Suite 340, Golden Valley, Minnesota, serving men from Minneapolis, St. Paul, and the surrounding Twin Cities area. North Star Prostate Center is structured to help men understand their prostate condition and available treatment paths, not simply to determine whether they qualify for PAE. By combining urologic evaluation with PAE expertise, the center can help patients comparing PAE vs. Rezum review prostate size, anatomy, urinary symptoms, bladder function, medication history, previous treatment, recovery considerations, and personal priorities before determining the next step. Learn more about BPH and enlarged prostate care, review North Star’s PAE treatment information, or contact the center to request an evaluation.
Medical disclaimer: This article is for general educational purposes and is not a substitute for individual medical advice. BPH treatment depends on the cause and severity of urinary symptoms, prostate size and anatomy, bladder function, medical history, medications, prior procedures, and personal goals. A qualified clinician should determine which options are appropriate for an individual patient.
Receiving lab results showing an elevated Prostate Specific Antigen level can be an incredibly stressful experience. The immediate thought for many men is a concern about prostate cancer. While PSA testing is a vital tool for detecting early stage malignancies, the reality is that a high PSA number does not automatically mean cancer is present.
At North Star Prostate Center, we frequently see patients who have been referred due to high PSA levels. Our goal is to provide clear information and effective solutions. Understanding the various factors that influence PSA levels is the first step toward making informed decisions about your urological health. This article explores the non cancerous reasons for elevated PSA,
Understanding Prostate Specific Antigen
Prostate Specific Antigen is a protein produced by both normal and abnormal cells in the prostate gland. Its primary biological function is to liquefy semen, allowing sperm to swim freely. A small amount of this protein naturally leaks into the bloodstream, which is what a PSA blood test measures.
When the prostate gland is healthy and normal in size, the amount of PSA in the blood remains relatively low. However, when the architecture of the prostate is disrupted, more PSA can escape into the bloodstream. This disruption can be caused by cancer cells, which often lack the normal cellular boundaries that keep PSA contained, but it can also be caused by entirely benign conditions.
According to research, the specificity of PSA screening is relatively low, meaning that while the test is very good at detecting when something is abnormal with the prostate, it is not very good at specifying exactly what that abnormality is. In clinical practice, up to ninety percent of individuals with elevated serum PSA levels do not have prostate cancer.
Benign Prostatic Hyperplasia as a Primary Cause of Elevated PSA
One of the most common non cancerous causes of an elevated PSA is benign prostatic hyperplasia. BPH is a non malignant enlargement of the prostate gland that occurs naturally as men age. As the prostate grows, it can compress the urethra, leading to bothersome lower urinary tract symptoms such as frequent urination, a weak stream, and difficulty emptying the bladder.
The relationship between BPH and PSA is straightforward: a larger prostate has more tissue, and more tissue produces more PSA. Studies have consistently shown a strong correlation between prostate volume and serum PSA levels. In fact, research indicates that up to eighty six percent of individuals with benign prostatic hyperplasia may have elevated levels of serum PSA.
Because BPH is so prevalent affecting approximately fifty percent of men in their fifties and up to eighty percent of men over seventy it is a leading driver of elevated PSA results in older men. When evaluating a high PSA, healthcare providers must consider the size of the prostate gland. A metric known as PSA density, which divides the total PSA level by the volume of the prostate, is often used to help guide biopsy decisions in patients with BPH. A large prostate with a moderately elevated PSA may have a low PSA density, suggesting the elevation is due to BPH rather than malignancy.
If you are experiencing symptoms of an enlarged prostate, you can learn more about the condition by visiting our understanding BPH page.
Other Non Cancerous Causes of High PSA
In addition to BPH, several other benign conditions and everyday activities can cause a temporary or chronic spike in PSA levels.
Prostatitis and Urinary Tract Infections
Inflammation or infection of the prostate gland, known as prostatitis, can cause significant spikes in PSA levels. Acute bacterial prostatitis can result in extremely high PSA readings. While rare, medical case reports have documented PSA levels exceeding one thousand nanograms per milliliter purely from severe acute infection. This occurs because the severe inflammation disrupts the cellular barriers within the prostate, allowing large amounts of PSA to flood into the bloodstream. Similarly, a standard urinary tract infection can also cause a temporary elevation. In these cases, PSA levels typically return to normal after the infection is successfully treated with antibiotics.
Medical Procedures and Physical Trauma
Any physical manipulation of the prostate can cause a transient rise in PSA. This includes medical procedures such as a digital rectal exam, the placement of a urinary catheter, or a prostate biopsy. Even activities that put pressure on the perineum, such as vigorous bicycle riding, have been known to cause mild, temporary elevations. It is generally recommended to avoid these activities and delay PSA testing if a recent procedure or infection has occurred.
Age Related Changes
PSA levels naturally increase as men age, even in the absence of significant BPH or cancer. This is why urologists often use age specific reference ranges when interpreting PSA results. A PSA level that might be considered suspiciously high for a forty year old man may be completely normal for a seventy five year old man.
The Role of Free vs Total PSA
When a total PSA level is elevated, doctors often order a secondary test that measures the ratio of free PSA to total PSA. In the bloodstream, PSA exists in two forms: bound to proteins and floating freely.
Research has demonstrated that the ratio of free to total PSA is a valuable tool for differentiating between BPH and prostate cancer. Men with prostate cancer tend to have a lower percentage of free PSA, while men whose elevated PSA is caused by benign conditions like BPH typically have a higher percentage of free PSA. This ratio helps clinicians determine whether a prostate biopsy is truly necessary, thereby reducing the number of unnecessary and potentially harmful procedures.
Addressing Elevated PSA Caused by BPH
If a thorough medical evaluation determines that your elevated PSA is due to benign prostatic hyperplasia, the focus shifts from cancer screening to symptom management and improving your quality of life. At North Star Prostate Center, we specialize in advanced, minimally invasive treatments for an enlarged prostate.
One of the most effective modern treatments is Prostate Artery Embolization. PAE is a minimally invasive procedure performed by an interventional radiologist. It involves navigating a tiny catheter into the arteries that supply blood to the prostate gland and releasing microscopic particles to block the blood flow. Deprived of its blood supply, the overgrown prostate tissue shrinks over time.
Clinical studies have shown that PAE is highly effective at reducing the size of the prostate and alleviating lower urinary tract symptoms. Furthermore, because the procedure shrinks the volume of the prostate gland, it naturally leads to a reduction in PSA levels. Research has demonstrated a statistically significant decrease in prostate volume and PSA values following the PAE procedure. In a prospective clinical study, the mean PSA value dropped from 4.9 ng/dL before the procedure to 2.8 ng/dL twelve months after PAE.
PAE offers several advantages over traditional surgical options like Transurethral Resection of the Prostate. It is performed on an outpatient basis, requires only moderate sedation rather than general anesthesia, and carries a significantly lower risk of sexual side effects. You can read a detailed comparison on our PAE or TURP page.
Moving Forward with Confidence
An elevated PSA level is a signal that your prostate requires medical attention, but it is not a definitive diagnosis of cancer. Benign prostatic hyperplasia, prostatitis, and even the natural aging process are common, non cancerous reasons for high PSA readings.
If you have been told your PSA is elevated and you are experiencing symptoms of an enlarged prostate, a comprehensive evaluation is essential. By utilizing tools like PSA density and the free to total PSA ratio, healthcare providers can accurately diagnose the underlying cause and recommend the most appropriate course of action.
We are dedicated to providing innovative solutions for men suffering from BPH. If your elevated PSA is linked to an enlarged prostate, minimally invasive procedures like Prostate Artery Embolization offer a safe and effective way to reduce prostate volume, lower PSA levels, and restore your quality of life.
Frequent urination at night in men is one of the most common reasons men begin searching for answers about prostate health. The medical term for waking from sleep to urinate is nocturia, and clinical literature describes nocturia as waking during the night one or more times to void after sleep has begun and before sleep resumes. Research published in the World Journal of Men’s Health found that nocturia can have a strong impact on sleep quality in men with lower urinary tract symptoms and benign prostatic hyperplasia, also called BPH or enlarged prostate. In that study, men with nocturia had worse sleep quality scores than men without nocturia, and the number of nighttime bathroom trips was linked with poorer sleep quality in a measurable way.
At North Star Prostate Center, we often hear from men who describe the same pattern. Sleep begins normally, then bathroom trips start interrupting the night. Over time, that routine can affect energy, focus, mood, and daily comfort. Nighttime urination can be related to BPH, but it can also come from other urinary, sleep, medication, heart, kidney, or metabolic factors. That is why a careful evaluation matters. The goal is not only to reduce bathroom trips, but also to understand why they are happening.
What Frequent Urination at Night Means
Frequent urination at night in men does not always mean the prostate is the only problem. Nocturia is a symptom, not a diagnosis. A peer reviewed review in Current Evaluation and Treatment of Nocturia explains that causes can include bladder storage problems, increased urine output, sleep disturbance, and other medical conditions. In practical terms, some men wake because the bladder feels full too often. Others produce too much urine overnight. Some wake because of poor sleep and then notice the need to urinate after they are already awake.
This distinction is important because treatment depends on the cause. A man with BPH related blockage may need a different plan than a man whose main issue is high nighttime urine production, untreated sleep apnea, evening diuretic use, or fluid timing. A symptom led search for frequent urination at night men can point someone toward prostate education, but a clinician needs to look at the full picture before recommending treatment.
How BPH Can Cause Nighttime Urination
BPH is a common, not cancerous enlargement of the prostate that becomes more common with age. The prostate surrounds part of the urethra, which is the tube that carries urine out of the bladder. As the prostate enlarges, it can narrow the urinary channel and make the bladder work harder to empty. Peer reviewed research in Frontiers in Aging Neuroscience describes BPH related lower urinary tract symptoms as including urinary retention, weak urine flow, and increased nocturia among men.
When the bladder has to push against resistance, several changes can occur. The bladder may become more sensitive. It may signal the urge to urinate even when it is not very full. It may not empty completely, which can leave urine behind after a bathroom trip. This can contribute to another urge to urinate later, including during the night. A study in the World Journal of Men’s Health also notes that nocturia is one of the common lower urinary tract symptoms in men with BPH and can be especially bothersome because it interrupts sleep.
BPH can also affect sleep indirectly. A man may go to bed expecting to wake, sleep more lightly because of that concern, or feel less rested because the deeper stages of sleep are interrupted. Over time, repeated waking can turn a urinary issue into a sleep quality issue as well.
Why Nighttime Urination Disrupts Sleep
Sleep is not just time spent in bed. Restorative sleep depends on moving through sleep cycles with as few interruptions as possible. In men with lower urinary tract symptoms and BPH, research has found that nocturia is associated with worse Pittsburgh Sleep Quality Index scores, which are commonly used in clinical studies to measure sleep quality. In the World Journal of Men’s Health study, men with nocturia had a higher mean sleep quality score, meaning worse sleep quality, than men without nocturia. The study also found a higher percentage of severe sleep disorders among men with nocturia.
Poor sleep can affect daily function. The same study discussed daytime fatigue and lower general well being as important consequences of nocturia. A larger cross sectional study in Frontiers in Aging Neuroscience involving more than eleven thousand men also found a significant association between poor sleep quality and higher prevalence of lower urinary tract symptoms and BPH, especially among older men. These findings support what many patients already know from experience: frequent urination at night in men can affect more than the bladder.
Common Causes Besides BPH
BPH is a major cause to consider, but it is not the only reason men wake to urinate. A review article on nocturia evaluation explains that nighttime urination can come from several broad categories, including increased nighttime urine production, reduced bladder capacity, sleep disorders, and other health conditions. This is why self diagnosing based on symptoms alone can be misleading.
Evening fluids can contribute, especially when a large amount is consumed close to bedtime. Alcohol and caffeine may also affect urine production or bladder irritation in some people. Certain medications, including diuretics, can increase urine output depending on timing. Sleep disorders may also play a role, because a person who wakes for another reason may notice bladder sensation that would not otherwise have caused a full awakening.
Medical conditions may contribute as well. Diabetes, fluid retention, kidney issues, heart related fluid shifts, urinary tract infection, and bladder dysfunction can all be part of the evaluation. A careful history helps separate BPH related urinary obstruction from other causes of nocturia.
What Evaluation May Include
Evaluation for frequent urination at night in men usually begins with a conversation about symptoms. We want to understand how many times a patient wakes, how long the pattern has been occurring, whether the urinary stream is weak, whether there is urgency, whether the bladder feels empty afterward, and whether daytime urination is also frequent. These details help determine whether symptoms fit a BPH pattern or point toward another cause.
A clinician may also review current medications, fluid timing, caffeine and alcohol intake, sleep quality, medical history, and prior prostate testing. Depending on the situation, evaluation may include a urine test, prostate exam, PSA discussion, bladder emptying measurement, imaging, or urinary flow testing. A bladder diary may be useful because nocturia research emphasizes the value of identifying the pattern behind nighttime urination. Tracking when fluids are consumed, how often urination occurs, and approximate urine volume can help distinguish high nighttime urine production from bladder storage issues or obstruction.
The most important point is that evaluation should guide treatment. Nocturia caused mainly by BPH may be approached differently than nocturia caused mainly by sleep disruption, fluid timing, medication timing, or another medical issue.
Treatment Depends on the Cause
Because nocturia has multiple possible causes, there is no single treatment that fits every patient. Some men benefit from adjusting evening fluid intake, limiting bladder irritants, changing medication timing under clinician guidance, or treating an underlying sleep or medical condition. Men whose symptoms are tied to BPH may need prostate focused care.
BPH treatment can include observation, medications, minimally invasive options, and surgical procedures, depending on symptom severity, prostate anatomy, bladder function, overall health, and patient goals. For some men, medication may improve urinary symptoms. For others, medication is not enough, side effects become a concern, or a procedure becomes the next appropriate step.
At North Star Prostate Center, the BPH treatment we offer is Prostate Artery Embolization, also called PAE. PAE is a minimally invasive procedure designed to reduce blood flow to selected areas of the enlarged prostate, which can help the prostate shrink over time and relieve lower urinary tract symptoms related to BPH. A peer reviewed review in the Journal of Clinical Medicine describes PAE as a treatment option for lower urinary tract symptoms due to BPH and emphasizes the importance of patient evaluation and selection.
A systematic review and meta analysis in Clinical Interventions in Aging evaluated PAE for lower urinary tract symptoms related to BPH and reported significant improvements from baseline in symptom scores, quality of life scores, peak urinary flow, and post void residual volume during follow up. The authors also noted that larger studies and longer follow up are needed, which is why we present PAE in a balanced way and focus on whether it is appropriate for each patient.
How PAE May Help BPH Related Nighttime Urination
When frequent urination at night in men is related to BPH, reducing prostate related blockage may help improve the urinary pattern. PAE does not treat every possible cause of nocturia. For example, if nighttime urination is mainly related to sleep apnea, high nighttime urine production, or medication timing, prostate treatment alone may not fully solve the issue. However, when BPH is a major contributor, improving lower urinary tract symptoms may reduce the burden that the enlarged prostate places on the bladder.
PAE may be considered for men with bothersome BPH symptoms who are seeking a minimally invasive option and who are appropriate candidates after evaluation. Men can also review our guide on what to expect when preparing for Prostate Artery Embolization for a clearer understanding of the patient experience.
When to Seek Care for Nighttime Urination
Nighttime urination deserves evaluation when it becomes persistent, affects sleep, interferes with daily energy, or occurs with other urinary symptoms such as weak stream, urgency, hesitancy, dribbling, incomplete emptying, or repeated trips to the bathroom. It is especially important to seek prompt care for inability to urinate, blood in the urine, fever, pain, or sudden severe urinary changes.
Frequent urination at night in men is common, but common does not mean it should be ignored. The symptom can provide an early clue about BPH, bladder function, sleep quality, and overall health. A thoughtful evaluation can identify the likely cause and help match treatment to the patient’s needs.
Takeaway
Frequent urination at night in men can interrupt sleep and affect quality of life. BPH is one possible cause because an enlarged prostate can contribute to urinary obstruction, bladder sensitivity, incomplete emptying, and repeated nighttime bathroom trips. Academic research links nocturia with poorer sleep quality in men with lower urinary tract symptoms and BPH, but the cause can vary from person to person.
At North Star Prostate Center, we focus on identifying whether BPH is driving the symptoms and whether Prostate Artery Embolization may be an appropriate option. The right treatment begins with the right diagnosis, especially when sleep and urinary health are both involved.